Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Gainers

  • Vivos Therapeutics, Inc. VVOS shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.
  • Crown ElectroKinetics Corp. CRKN climbed 162% to $0.4909 after the company announced it acquired Amerigen 7.
  • Cryptyde, Inc. TYDE gained 108% to $0.4022.
  • Geron Corporation GERN shares jumped 53.3% to $3.6800 after the company announced top-line results from the IMerge Phase 3 trial of imetelstat in lower risk MDS. The trial met the primary 8-week transfusion independence (TI) endpoint and key secondary 24-week TI endpoint.
  • Shift Technologies, Inc. SFT rose 49% to $0.2350.
  • Neptune Wellness Solutions Inc. NEPT jumped 42.4% to $0.4132. The company earlier reported in 13G filing Sabby Volatility Warrant Master Fund held 11% stake in Neptune Wellness Solutions.
  • Reunion Neuroscience Inc. REUN gained 27.8% to $1.33.
  • Armata Pharmaceuticals, Inc. ARMP surged 25% to $ 1.3799.
  • AIM ImmunoTech Inc. AIM jumped 23.3% to $ 0.3997.
  • NuZee, Inc. NUZE gained 21.8% to $12.85. NuZee adopted a 1-for-35 reverse stock split.
  • Atlis Motor Vehicles, Inc. AMV shares climbed 21.4% to $3.69.
  • ZK International Group Co., Ltd. ZKIN jumped 20% to $0.50.
  • Elys Game Technology, Corp. ELYS shares gained 20% to $0.3089 after dropping 8% on Tuesday. Elys Game Technology and Cloakbook were recently granted a license to commence sportsbook operations in Washington, D.C.
  • Lizhi Inc. LIZI rose 19.6% to $0.67 after declining around 3% on Tuesday.
  • Galmed Pharmaceuticals Ltd. GLMD jumped 19.5% to $ 0.8498. Galmed reported results from the open-label part of the ARMOR study.
  • ASLAN Pharmaceuticals Limited ASLN surged 18.4% to $0.5150. ASLAN Pharmaceuticals and Thermo Fisher Scientific reported a partnership to manufacture high concentration formulation of eblasakimab for future studies.
  • Dada Nexus Limited DADA gained 18.4% to $10.45. Shares of Chinese companies traded higher after Chinese regulators reportedly approved a capital raise for Ant Group.
  • Eloxx Pharmaceuticals, Inc. ELOX gained 16.4% to $3.05. Eloxx Pharmaceuticals, last month, announced a 1-for-40 reverse stock split.
  • Oblong, Inc. OBLG shares rose 15.6% to $2.02 after the company reported a 1-for-15 reverse stock split.
  • Baozun Inc. BZUN gained 15.3% to $6.50.
  • Eliem Therapeutics, Inc. ELYM gained 15.1% to $3.81.
  • I-Mab IMAB rose 15% to $4.88.
  • Genprex, Inc. GNPX gained 14.2% to $1.8150.
  • GDS Holdings Limited GDS jumped 13.8% to $27.00. Shares of Chinese companies traded higher after Chinese regulators reportedly approved a capital raise for Ant Group.
  • Kingsoft Cloud Holdings Limited KC rose 13.2% to $4.46. Kingsoft Cloud Holdings recently successfully listed on Hong Kong Stock Exchange. Shares of Chinese companies traded higher after Chinese regulators reportedly approved a capital raise for Ant Group.
  • Poseida Therapeutics, Inc. PSTX gained 13% to $6.54. HC Wainwright & Co. initiated coverage on Poseida Therapeutics with a Buy rating and announced a price target of $15.
  • Deciphera Pharmaceuticals, Inc. DCPH gained 12.3% to $17.90. Deciphera Pharmaceuticals announced an exploratory analysis of data from the INTRIGUE Phase 3 study of Qinlock using circulating tumor DNA (ctDNA).
  • InMed Pharmaceuticals Inc. INM rose 8.7% to $2.40 after gaining over 9% on Tuesday.


Losers

  • Vera Therapeutics, Inc. VERA shares tumbled 64.5% to $6.51 after the company announced topline results of the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy.
  • Enovix Corporation ENVX dropped 43% to $6.80 following a livestream presentation from company management regarding an update on production, commercialization and recent management additions.
  • ReShape Lifesciences Inc. RSLS fell 33.8% to $10.35 after climbing 132% on Tuesday. Reshape Lifesciences recently announced a 1-for-50 reverse stock split.
  • Phathom Pharmaceuticals, Inc. PHAT fell 32.8% to $6.80. The FDA notified Phathom Pharmaceuticals that no action would be taken on the company's new drug application (NDA) for vonoprazan, under review as a treatment for erosive esophagitis, on or before the current Prescription Drug User Fee Act (PDUFA) target action date of January 11, 2023.
  • Moolec Science SA MLEC dropped 31.8% to $6.21.
  • 180 Life Sciences Corp. ATNF dropped 29% to $3.76. 180 Life Sciences announced publication of a review on the biological basis of Dupuytren's disease in the Journal Trends in Molecular Medicine.
  • Lucira Health, Inc. LHDX fell 24.5% to $0.4525. Lucira Health shares jumped 440% on Tuesday after the company announced it submitted an Emergency Use Authorization application to the FDA for OTC use of its COVID-19 & Flu test.
  • Innovid Corp. CTV dropped 23.8% to $1.37.
  • Jasper Therapeutics, Inc. JSPR fell 22.2% to $2.13. Jasper Therapeutics shares jumped 476% on Tuesday after the company announced data from the first three participants in a Phase 1/2 clinical trial evaluating the addition of briquilimab (JSP191) to an existing bone marrow transplantation regimen in individuals with sickle cell disease (SCD) and beta-thalassemia.
  • Kidpik Corp. PIK fell 17.8% to $0.7151.
  • Gelesis Holdings, Inc. GLS dropped 17.3% to $0.43.
  • Airspan Networks Holdings Inc. MIMO fell 15% to $1.13.
  • Seer, Inc. SEER dropped 14.2% to $5.02 after B of A Securities downgraded the stock from Neutral to Underperform and lowered its price target from $9 to $6.50.
  • Swvl Holdings Corp. SWVL fell 13.3% to $0.1631. Swvl recently announced the commencement of a strategic review process.
  • Timber Pharmaceuticals, Inc. TMBR dropped 12.9% to $2.0550.
  • Chemomab Therapeutics Ltd. CMMB fell 11.6% to $2.60. Chemomab Therapeutics recently reported topline results from its Phase 2a trial assessing CM-101 in non-alcoholic steatohepatitis (NASH) patients.
  • Dragonfly Energy Holdings Corp. DFLI dropped 9.1% to $10.93.
  • VEON Ltd. VEON declined 7.7% to $0.48.
  • MiNK Therapeutics, Inc. INKT fell 7.3% to $2.30.

Also Check This Out $1.2 Million Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksSmall CapIntraday UpdateMarketsMoversTrading IdeasIndustrialsMid-Day MoversTop GainersTrading Companies & Distributors
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!